Burnett Patrick 4
4 · Arcutis Biotherapeutics, Inc. · Filed Aug 21, 2025
Insider Transaction Report
Form 4
Burnett Patrick
See Remarks
Transactions
- Sale
Common Stock
2025-08-21$15.57/sh−2,438$37,969→ 104,811 total - Sale
Common Stock
2025-08-19$16.16/sh−1,750$28,281→ 107,249 total
Footnotes (4)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.87 to $16.73, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.
- [F4]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.43 to $15.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.